GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » COGS-to-Revenue

Diagnamed Holdings (XCNQ:DMED) COGS-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Diagnamed Holdings COGS-to-Revenue?

Diagnamed Holdings's Cost of Goods Sold for the three months ended in Dec. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was C$0.00 Mil.

Diagnamed Holdings's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Diagnamed Holdings's Gross Margin % for the three months ended in Dec. 2024 was N/A%.


Diagnamed Holdings COGS-to-Revenue Historical Data

The historical data trend for Diagnamed Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnamed Holdings COGS-to-Revenue Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23 Sep24
COGS-to-Revenue
- - - -

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Diagnamed Holdings COGS-to-Revenue Calculation

Diagnamed Holdings's COGS to Revenue for the fiscal year that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Diagnamed Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diagnamed Holdings  (XCNQ:DMED) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Diagnamed Holdings's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Diagnamed Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnamed Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Executives
Fabio Chianelli Director, Senior Officer

Diagnamed Holdings Headlines

No Headlines